Search

Your search keyword '"Touraine Philippe A."' showing total 7 results
Start Over Author "Touraine Philippe A." Journal endocrine connections
7 results on '"Touraine Philippe A."'

2. The genetic diagnosis of rare endocrine disorders of sex development and maturation: a survey among Endo-ERN centres

Author

Persani, Luca, primary, Cools, Martine, additional, Ioakim, Stamatina, additional, Faisal Ahmed, S, additional, Andonova, Silvia, additional, Avbelj-Stefanija, Magdalena, additional, Baronio, Federico, additional, Bouligand, Jerome, additional, Bruggenwirth, Hennie T, additional, Davies, Justin H, additional, De Baere, Elfride, additional, Dzivite-Krisane, Iveta, additional, Fernandez-Alvarez, Paula, additional, Gheldof, Alexander, additional, Giavoli, Claudia, additional, Gravholt, Claus H, additional, Hiort, Olaf, additional, Holterhus, Paul-Martin, additional, Juul, Anders, additional, Krausz, Csilla, additional, Lagerstedt-Robinson, Kristina, additional, McGowan, Ruth, additional, Neumann, Uta, additional, Novelli, Antonio, additional, Peyrassol, Xavier, additional, Phylactou, Leonidas A, additional, Rohayem, Julia, additional, Touraine, Philippe, additional, Westra, Dineke, additional, Vezzoli, Valeria, additional, and Rossetti, Raffaella, additional

Published
2022
Full Text
View/download PDF

3. Puberty and fertility in classic galactosemia

Author

Flechtner, Isabelle, primary, Viaud, Magali, additional, Kariyawasam, Dulanjalee, additional, Perrissin-Fabert, Marie, additional, Bidet, Maud, additional, Bachelot, Anne, additional, Touraine, Philippe, additional, Labrune, Philippe, additional, de Lonlay, Pascale, additional, and Polak, Michel, additional

Published
2021
Full Text
View/download PDF

4. Transition of young adults with endocrine and metabolic diseases: the ‘TRANSEND’ cohort

Author

Le Roux, Enora, primary, Menesguen, Florence, additional, Tejedor, Isabelle, additional, Popelier, Marc, additional, Halbron, Marine, additional, Faucher, Pauline, additional, Malivoir, Sabine, additional, Pinto, Graziella, additional, Léger, Juliane, additional, Hatem, Stephane, additional, Polak, Michel, additional, Poitou, Christine, additional, and Touraine, Philippe, additional

Published
2021
Full Text
View/download PDF

7. Comparison of modified-release hydrocortisone capsules versus prednisolone in the treatment of congenital adrenal hyperplasia.

Author

Rees DA, Merke DP, Arlt W, Brac De La Perriere A, Hirschberg AL, Juul A, Newell-Price J, Prete A, Reisch N, Stikkelbroeck NM, Touraine PA, Lewis A, Porter J, Coope H, and Ross RJ

Abstract

Background: Prednisolone and prednisone are recommended treatment options for adults with congenital adrenal hyperplasia (CAH); however, there is no randomised comparison of prednis(ol)one with hydrocortisone., Design: Six-month open-label randomised phase 3 study and interim analysis of a single-arm extension study was the design of the study., Methods: The method of the study was hydrocortisone dose equivalent and 09:00-h 17-hydroxyprogesterone (17OHP) from 48 patients taking prednis(ol)one at baseline., Results: At baseline, the median hydrocortisone dose equivalent was 30 mg/day and 17OHP was < 36 nmol/L (3× upper limit of normal) in 56% of patients. Patients were randomised to continue prednis(ol)one or switch to modified-release hydrocortisone capsule (MRHC) at the same hydrocortisone-equivalent dose. At 4 weeks, 94% on MRHC and 71% on prednis(ol)one had 17OHP < 36 nmol/L. At 18 months in the extension study of MRHC, the median MRHC dose was 20 mg/day and 82% had 17OHP < 36 nmol/L. The per cent of patients with 17OHP < 36 nmol/L on a hydrocortisone dose equivalent ≤ 25 mg/day was greater at 18 months in the extension study on MRHC than while on prednis(ol)one at baseline: 57% vs 27%, P = 0.04. In the randomised study, no patients had an adrenal crisis on MRHC and one on prednisolone. In the extension study (221 patient years), there were 12 adrenal crises in 5 patients (5.4/100 patient years)., Conclusion: MRHC reduces 17OHP at 09:00 h compared to prednis(ol)one and the dose of MRHC can be down-titrated over time in the majority of patients.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results